XSES
P8A
Market cap26mUSD
Sep 07, Last price
0.13SGD
Name
Cordlife Group Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As an investment holding company, Cordlife Group Limited offers cord blood banking solutions across various countries including Singapore, Hong Kong, India, Malaysia, and the Philippines, extending its reach globally. Its operations are structured into two distinct segments: Banking and Diagnostics. The Banking segment is dedicated to the processing and secure storage of stem cells derived from cord blood, cord lining, and cord tissue. Meanwhile, its Diagnostics arm delivers a suite of screening services, such as non-invasive prenatal testing, pediatric vision evaluations, and genetic and metabolic screenings for newborns. Furthermore, Cordlife extends its diagnostic offerings to include specialized procedures like preimplantation genetic screening, endometrial receptivity testing, pediatric allergen analysis, and genetic talent assessments. It also supports parents through "moms up," a mobile application providing valuable resources for pregnancy and parenting. Beyond its core medical services, the company engages in management, marketing, and property investment activities. Established in 2001, Cordlife Group Limited maintains its corporate headquarters in Singapore.
Key people
Poh Lan Tan
Group Chief Executive Officer, Executive Director · since 2019
Choo Boon Yong
Group Chief Financial Officer · since 2017
Hnin Yi Thet
Group Finance Director · since 2017
Michael Steven Weiss
Group Chief Executive Officer, Executive Director · since 2018
Siew Koon Ang
Company Secretary
Vice Chairman of the Board · since 2016
Chien Chang
Non-Independent Non-Executive Director · since 2019
Bing Chuen Chen
Non-Independent Non-Executive Director · since 2016
Lin Wang
Non-Independent Non-Executive Director · since 2019
Lingyun Zhai
Non-Independent Non-Executive Director · since 2019
Independent Director · since 2011
Hwee Tiong Yeo
Independent Director · since 2018
Non-Executive Independent Director · since 2014
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||